In vitro Activities of A-Gliadin-Related Synthetic Peptides

Damaging Effect on the Atrophic Coeliac Mucosa and Activation of Mucosal Immune Response in the Treated Coeliac Mucosa

L. Maiuri, R. Troncone, M. Mayer, S. Coletta, A. Picarelli, M. De Vincenzi, V. Pavone, S. Auricchio

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

Background: Gliadin amino acid sequence(s) responsible for toxicity in susceptible individuals have not been fully elucidated. Previous in vitro studies have suggested the presence of active sequences in the NH2-terminal part of the A-gliadin molecule. In this paper the in vitro activity of A-gliadin synthetic peptides 31-55, 31-43, and 44-55 has been investigated. Methods: Organ culture of jejunal mucosa from untreated and treated coeliac patients was used. In the first system enterocyte height was used as a measure of peptide toxicity; in the second system evidence of activated mucosal cell-mediated immune response was sought. Results: Peptides 31-55 and 31-43 were active on untreated coeliac mucosa at a concentration of 0.5 mg/ml and peptide 44-55 only at a concentration of 3 mg/ml. In in vitro-cultured treated coeliac mucosa peptides 31-55 and 31-43 at 1 mg/ml and peptide 44-55 at 3 mg/ml were able to induce enhanced epithelial expression of HLA-DR and 4F2 molecules and the appearance of CD25-positive cells. Conclusions: Our results suggest that 31-43 and 44-55 A-gliadin peptides are both active, even if to different extents. In vitro systems remain essential tools to screen material to be subsequently tested in vivo.

Original languageEnglish
Pages (from-to)247-253
Number of pages7
JournalScandinavian Journal of Gastroenterology
Volume31
Issue number3
Publication statusPublished - 1996

Fingerprint

Gliadin
Mucosal Immunity
Abdomen
Mucous Membrane
Peptides
Enterocytes
Organ Culture Techniques
HLA-DR Antigens
In Vitro Techniques
Amino Acid Sequence

Keywords

  • Coeliac disease
  • Gliadin
  • Mucosal immunity
  • Organ culture

ASJC Scopus subject areas

  • Gastroenterology

Cite this

In vitro Activities of A-Gliadin-Related Synthetic Peptides : Damaging Effect on the Atrophic Coeliac Mucosa and Activation of Mucosal Immune Response in the Treated Coeliac Mucosa. / Maiuri, L.; Troncone, R.; Mayer, M.; Coletta, S.; Picarelli, A.; De Vincenzi, M.; Pavone, V.; Auricchio, S.

In: Scandinavian Journal of Gastroenterology, Vol. 31, No. 3, 1996, p. 247-253.

Research output: Contribution to journalArticle

Maiuri, L. ; Troncone, R. ; Mayer, M. ; Coletta, S. ; Picarelli, A. ; De Vincenzi, M. ; Pavone, V. ; Auricchio, S. / In vitro Activities of A-Gliadin-Related Synthetic Peptides : Damaging Effect on the Atrophic Coeliac Mucosa and Activation of Mucosal Immune Response in the Treated Coeliac Mucosa. In: Scandinavian Journal of Gastroenterology. 1996 ; Vol. 31, No. 3. pp. 247-253.
@article{e89c24d94bbd465d98f0206ff2687f26,
title = "In vitro Activities of A-Gliadin-Related Synthetic Peptides: Damaging Effect on the Atrophic Coeliac Mucosa and Activation of Mucosal Immune Response in the Treated Coeliac Mucosa",
abstract = "Background: Gliadin amino acid sequence(s) responsible for toxicity in susceptible individuals have not been fully elucidated. Previous in vitro studies have suggested the presence of active sequences in the NH2-terminal part of the A-gliadin molecule. In this paper the in vitro activity of A-gliadin synthetic peptides 31-55, 31-43, and 44-55 has been investigated. Methods: Organ culture of jejunal mucosa from untreated and treated coeliac patients was used. In the first system enterocyte height was used as a measure of peptide toxicity; in the second system evidence of activated mucosal cell-mediated immune response was sought. Results: Peptides 31-55 and 31-43 were active on untreated coeliac mucosa at a concentration of 0.5 mg/ml and peptide 44-55 only at a concentration of 3 mg/ml. In in vitro-cultured treated coeliac mucosa peptides 31-55 and 31-43 at 1 mg/ml and peptide 44-55 at 3 mg/ml were able to induce enhanced epithelial expression of HLA-DR and 4F2 molecules and the appearance of CD25-positive cells. Conclusions: Our results suggest that 31-43 and 44-55 A-gliadin peptides are both active, even if to different extents. In vitro systems remain essential tools to screen material to be subsequently tested in vivo.",
keywords = "Coeliac disease, Gliadin, Mucosal immunity, Organ culture",
author = "L. Maiuri and R. Troncone and M. Mayer and S. Coletta and A. Picarelli and {De Vincenzi}, M. and V. Pavone and S. Auricchio",
year = "1996",
language = "English",
volume = "31",
pages = "247--253",
journal = "Scandinavian Journal of Gastroenterology",
issn = "0036-5521",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - In vitro Activities of A-Gliadin-Related Synthetic Peptides

T2 - Damaging Effect on the Atrophic Coeliac Mucosa and Activation of Mucosal Immune Response in the Treated Coeliac Mucosa

AU - Maiuri, L.

AU - Troncone, R.

AU - Mayer, M.

AU - Coletta, S.

AU - Picarelli, A.

AU - De Vincenzi, M.

AU - Pavone, V.

AU - Auricchio, S.

PY - 1996

Y1 - 1996

N2 - Background: Gliadin amino acid sequence(s) responsible for toxicity in susceptible individuals have not been fully elucidated. Previous in vitro studies have suggested the presence of active sequences in the NH2-terminal part of the A-gliadin molecule. In this paper the in vitro activity of A-gliadin synthetic peptides 31-55, 31-43, and 44-55 has been investigated. Methods: Organ culture of jejunal mucosa from untreated and treated coeliac patients was used. In the first system enterocyte height was used as a measure of peptide toxicity; in the second system evidence of activated mucosal cell-mediated immune response was sought. Results: Peptides 31-55 and 31-43 were active on untreated coeliac mucosa at a concentration of 0.5 mg/ml and peptide 44-55 only at a concentration of 3 mg/ml. In in vitro-cultured treated coeliac mucosa peptides 31-55 and 31-43 at 1 mg/ml and peptide 44-55 at 3 mg/ml were able to induce enhanced epithelial expression of HLA-DR and 4F2 molecules and the appearance of CD25-positive cells. Conclusions: Our results suggest that 31-43 and 44-55 A-gliadin peptides are both active, even if to different extents. In vitro systems remain essential tools to screen material to be subsequently tested in vivo.

AB - Background: Gliadin amino acid sequence(s) responsible for toxicity in susceptible individuals have not been fully elucidated. Previous in vitro studies have suggested the presence of active sequences in the NH2-terminal part of the A-gliadin molecule. In this paper the in vitro activity of A-gliadin synthetic peptides 31-55, 31-43, and 44-55 has been investigated. Methods: Organ culture of jejunal mucosa from untreated and treated coeliac patients was used. In the first system enterocyte height was used as a measure of peptide toxicity; in the second system evidence of activated mucosal cell-mediated immune response was sought. Results: Peptides 31-55 and 31-43 were active on untreated coeliac mucosa at a concentration of 0.5 mg/ml and peptide 44-55 only at a concentration of 3 mg/ml. In in vitro-cultured treated coeliac mucosa peptides 31-55 and 31-43 at 1 mg/ml and peptide 44-55 at 3 mg/ml were able to induce enhanced epithelial expression of HLA-DR and 4F2 molecules and the appearance of CD25-positive cells. Conclusions: Our results suggest that 31-43 and 44-55 A-gliadin peptides are both active, even if to different extents. In vitro systems remain essential tools to screen material to be subsequently tested in vivo.

KW - Coeliac disease

KW - Gliadin

KW - Mucosal immunity

KW - Organ culture

UR - http://www.scopus.com/inward/record.url?scp=0030006037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030006037&partnerID=8YFLogxK

M3 - Article

VL - 31

SP - 247

EP - 253

JO - Scandinavian Journal of Gastroenterology

JF - Scandinavian Journal of Gastroenterology

SN - 0036-5521

IS - 3

ER -